HC Wainwright Has Bearish Forecast for IPA FY2028 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Equities researchers at HC Wainwright cut their FY2028 earnings per share estimates for ImmunoPrecise Antibodies in a report issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.08 per share for the year, down from their prior estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2029 earnings at $0.17 EPS.

Separately, Benchmark reissued a “speculative buy” rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research note on Tuesday.

ImmunoPrecise Antibodies Trading Down 4.2 %

NASDAQ IPA opened at $0.36 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.01 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $11.20 million, a P/E ratio of -0.46 and a beta of 0.09. ImmunoPrecise Antibodies has a 52-week low of $0.27 and a 52-week high of $1.51. The firm has a 50-day moving average price of $0.43 and a 200 day moving average price of $0.47.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The company had revenue of $4.23 million during the quarter, compared to the consensus estimate of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC increased its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the period. Ingalls & Snyder LLC owned about 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the Securities and Exchange Commission. 6.70% of the stock is currently owned by institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.